PULM - Pulmatrix Inc Stock Price, Fair Value and News

$6.00+0.09 (+1.52%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

PULM Price Action

Last 7 days

4.4%

Last 30 days

6.8%

Last 90 days

174.0%

Trailing 12 Months

198.5%

PULM RSI Chart

PULM Valuation

Market Cap

21.9M

Price/Earnings (Trailing)

-2.27

Price/Sales (Trailing)

1.98

Price/Free Cashflow

-1.8

PULM Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

PULM Fundamentals

PULM Revenue

Revenue (TTM)

11.1M

Rev. Growth (Yr)

-79.12%

Rev. Growth (Qtr)

-86.02%

PULM Earnings

Earnings (TTM)

-9.7M

Earnings Growth (Yr)

31.45%

Earnings Growth (Qtr)

55.48%

PULM Profitability

Return on Equity

-88.42%

Return on Assets

-83.89%

Free Cashflow Yield

-55.53%

PULM Investor Care

Diluted EPS (TTM)

-2.64

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	11.7M	12.5M	11.1M	0
2023	6.4M	6.9M	6.8M	7.3M
2022	4.9M	4.0M	4.8M	6.1M
2021	11.3M	10.0M	6.7M	5.2M
2020	10.6M	9.3M	12.2M	12.6M
2019	0	5.0M	6.4M	8.0M
2018	605.5K	488.0K	153.0K	306.0K
2017	0	0	773.5K	513.5K
2016	1.5M	1.6M	992.0K	834.5K
2015	143.0K	309.0K	930.0K	1.2M
2014	0	0	0	352.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Pulmatrix Inc

Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; and a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of PUR1900. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.

CEO	Mr. Teofilo David Raad MBA
WEBSITE	pulmatrix.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	28

Pulmatrix Inc Frequently Asked Questions

What is the ticker symbol for Pulmatrix Inc? What does PULM stand for in stocks?

PULM is the stock ticker symbol of Pulmatrix Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Pulmatrix Inc (PULM)?

As of Fri Dec 20 2024, market cap of Pulmatrix Inc is 21.91 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PULM stock?

You can check PULM's fair value in chart for subscribers.

Is Pulmatrix Inc a good stock to buy?

The fair value guage provides a quick view whether PULM is over valued or under valued. Whether Pulmatrix Inc is cheap or expensive depends on the assumptions which impact Pulmatrix Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PULM.

What is Pulmatrix Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, PULM's PE ratio (Price to Earnings) is -2.27 and Price to Sales (PS) ratio is 1.98. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PULM PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Pulmatrix Inc's stock?

In the past 10 years, Pulmatrix Inc has provided -0.434 (multiply by 100 for percentage) rate of return.